Background: Treatment-related osteonecrosis (ON) is a serious complication of treatment of acute lymphoblastic leukemia (ALL).
INTRODUCTION
Cure rates of acute lymphoblastic leukemia (ALL) are increasing and reaching 90% in pediatric patients 1 and 70% in adults treated according to pediatric protocols. [2] [3] [4] [5] [6] Accordingly, this warrants focus on reducing both acute toxicities and late effects. 7 Osteonecrosis (ON) is a serious adverse event in children and young adults treated for ALL. The spectrum of symptomatic ON varies from transient pain and reduced physical capability to lifelong disability, need for arthroplastic surgery, and reduced quality of life. [8] [9] [10] However, risk factors may differ between severe and nonsevere ON, and may influence early diagnosis and options for intervention.
Symptomatic ON has been reported in 1.6 ̶ 17.6% of patients with ALL in contemporary protocols, and it occurs during or shortly after treatment. 11 Patients older than 10 years have a much higher incidence of ON. 8, [12] [13] [14] [15] [16] [17] Incidence reaching 26% has been reported in adolescent females, 18 although female sex as a risk factor is not consistent. 9, 15, 19 Glucocorticoids (GC) are regarded as the most important antileukemic drugs contributing to ON development 20 ; reduced risk has been reported when dexamethasone treatment during delayed intensification is administered alternate-weekly instead of continuously. 18 The Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL2008 treatment protocol includes either prednisolone or dexamethasone during induction and alternate-week dexamethasone during delayed intensification. 21 Asparaginase is given as pegylated asparaginase (PEG-ASP). We used prospectively collected toxicity registry data 22 and retrospectively designed a questionnaire survey to study in detail symptomatic ON in both children and young adults, aged 1-45 years, treated according to the NOPHO ALL2008 protocol. Our aims were to elucidate clinical characteristics of ON and to investigate potential risk factors for ON. Further, we described differences between patients developing nonsevere and severe ON in order to explore potential risk factors for severe ON, which may lead to life-long complications.
METHODS
This study was designed as a case-cohort study including a nested case-control study. The case-cohort part described overall and ageand sex-related ON incidence. The case-control study was designed to investigate potential risk factors for ON.
Patients
The total cohort included patients diagnosed with ALL from July 2008 to December 2014, treated according to the NOPHO ALL2008 protocol [21] [22] [23] (Supplementary Methods S1). Patients were aged 1-45 years at the time of ALL diagnosis with Philadelphia chromosome negative and either B-cell precursor or T-cell ALL (n = 1,509). We excluded patients who died before remission (n = 16) and patients not risk-group stratified (n = 2). The study was approved by the regional ethics institutional review board of the Capital Region of Denmark (Protocol no.: H-2-2010-002) and by ethics authorities in the other Nordic and Baltic countries as part of the NOPHO ALL2008 protocol. Informed consent from patients/families was obtained according to the Declaration of Helsinki.
ON registration and classification
Prospective toxicity registration of 19 predefined serious adverse events, including symptomatic ON, was performed. 22 All local centers were contacted to ensure full registration. ON diagnosis was based on verification by magnetic resonance images (MRI) or radiographs in local treatment centers. No screening was performed in asymptomatic patients. We collected data, including date of ON diagnosis confirmed by imaging, symptoms, first joint diagnosed, grade, and treatment for ON.
At the end of follow-up (August 27, 2015), 67 patients were registered with ON, and through contacts with treatment centers five F I G U R E 1 Flowchart of 1,509 Nordic and Baltic patients aged 1-45 years diagnosed with acute lymphoblastic leukemia (ALL) from July 2008 to December 2014. All patients were treated according to the NOPHO ALL2008 protocol. Patients were excluded if they could not be stratified to ALL risk group (n = 2) or due to death in remission (n = 16). At the end of follow-up (i.e., August 27, 2015) , 67 of 1,491 patients were registered with symptomatic osteonecrosis (ON), and during the survey an additional five patients were detected. From the ON group, patients were excluded due to (i) not having ON (n = 1), (ii) asymptomatic ON (n = 1), and (iii) ON after stem cell transplantation (SCT) (n = 1). Further, two patients with ON were excluded from the study as they had ON diagnosed before ALL diagnosis, giving in total an ALL cohort of 1,489 patients. Overall, we confirmed symptomatic ON in 67 patients additional patients with ON were identified; ON manifested in two of the 72 patients before ALL diagnosis and they were excluded (described in previous publication 24 ). Further, three patients were moved to the non-ON group of patients-one had been incorrectly registered, one had asymptomatic ON, and one had ON after hematopoietic stem cell transplantation (SCT) (Figure 1 ).
ON was classified according to the Ponte di Legno Toxicity Working
Group (PTWG) grading system. 7 When the questionnaire survey was conducted, the PTWG grading had not been published. 7 Therefore, the grading in the questionnaire was based on Common Terminology Criteria for Adverse Events version 4.03, 25 
Questionnaires
Data collection for the case-control study was a questionnaire targeting treating physicians. We individually matched two controls per patient with ON, matched on the bases of age at the time of ALL diagnosis and sex. Moreover, when possible, we matched subjects on the bases of country and ALL risk groups. If more than two controls were available for matching, those with date of ALL diagnosis closest to that of patients with ON were selected. To ensure maximal follow-up, we did not select controls with relapse within the first year of ALL therapy, patients who underwent SCT, or those who died during treatment. Additionally, we did a questionnaire study for patients with ON (Supplementary Methods S1).
All questionnaires, including questionnaires targeting physicians and patients/families, were validated for misinterpretation by two physicians/patients at University Hospital Copenhagen. Moreover, the questionnaires for patients were translated to the local language and therefore, in Denmark, validated by backwards translation. Questionnaires for physicians were returned for 118 of 134 controls (88%) and 65 of 67 patients with ON (97%). The response rate from patients/families was 21of 28 (75%).
Statistical analyses
The Kaplan-Meier method was used to show cumulative ON incidence, comparing groups using the Cox proportional hazards model adjusted for age and sex, stratified by risk group. Cumulative incidence was calculated at 5 years and censored for competing events, including SCT, relapse, second malignant neoplasm, and death.
In the case-control study, Cox models were fitted to compare patients with ON and controls in terms of potential risk factors. Variables occurring after ALL diagnosis were analyzed by using time of measurement as the start time in the Cox models (Supplementary Methods S1).
We compared patients with ON with regard to severity and surgery using logistic regression, adjusting for age at ALL diagnosis and sex.
Continuous variables within subgroups were compared using the Mann-Whitney Wilcoxon test or Kruskal-Wallis test. Chi-squared test was used for comparing medicine modifications and supplements.
RESULTS
We included 1,489 patients with ALL, of whom 67 patients ( 10.1-19.5) in male patients with ON (P = 0.057).
ON presentation
We received responses from physicians' questionnaires for 65 patients Table S2 ).
ON treatment
Of the 33 patients with ON grade 4, 15 had arthroplasty performed, including hips bilaterally (n = 9), hip unilaterally (n = 5), and shoulder unilaterally (n = 1). Prior to performing arthroplasty, one patient underwent core decompression and two patients, who had arthroplasty, had joint preserving surgery in another joint. In addition, five patients underwent joint preserving surgery, including core decompression (n = 1), epiphysiodesis (n = 1), osseograft (n = 1), cartilage replacement (n = 1), and femoral osteotomy (n = 1). Further, at the time of the survey, two patients with severe ON had hip arthroplasty planned when growth was completed. Lastly, one patient with ON had planned surgery of the knee and for three others, physicians reported that future surgery was potentially required. Thus, of the 33 patients with grade 4 disease, 20 (61%) had surgery, and of the remaining 13 patients, at least three were likely to have surgery. In addition, intervention modalities included physiotherapy (n = 41), analgesics (n = 52, of whom seven received intravenous morphine), calcium supplements (n = 43), vitamin D supplements (n = 45), bisphosphonates (n = 9), and immobilization (n = 17).
Timing of ON
Based on the physicians' questionnaires we received (n = 65), the Table S3 ). Compared with children Table S3 ). Table 1 presents adjusted and stratified analyses of potential risk factors for ON. The cumulative incidence of ON was significantly higher in adolescents (10.0-18.9 years) compared with younger children (1.0-9.9 years) (hazard ratio [HR] = 8.6, 95% CI: 4.9-15, P < 0.001), with a 5-year cumulative incidence of 20% (95% CI: 15-27) and 2.2% (95% CI: 1.4-3.3), respectively. The 5-year cumulative incidence of ON for adults (aged 19.0-45.0 years) was 15% (95% CI: 7.5-29), with a significantly higher incidence in adults compared with children 1.0-9.9 years old (HR = 5.1, 95% CI: 2.4-11, P < 0.001). Cumulative incidence of ON was similar in adolescents and adults (P = 0.167).
Risk factors for ON
The cumulative incidence of ON was significantly higher in female patients compared with male patients (HR = 1.8, 95% CI: 1.1-2.9, P = 0.024), with a 5-year cumulative incidence of 7.5% (95% CI: 5.5-10) and 5.2% (95% CI: 3.6-7.7), respectively. Cumulative incidences for and male adults (HR = 1.1, P = 0.848, P = 0.848), with a 5-year cumulative incidence in female adults of 12% (95% CI: 4.3-29) and 17% (95% CI: 6.9-37) for male adults ( Figure 3C ). The lowest incidence was found in young children, and there was a nonsignificant higher ON incidence in females compared with males (HR = 2.4, 95% CI: 0.9-6.2, P = 0.08) ( Figure 3A) . Importantly, 20 patients aged 1.0-9.9 years were diagnosed with ON, including six patients with developing severe ON, all of them females. We found no significant association between incidence of ON and ALL risk group (i.e., therapy arm), induction therapy (dexamethasone vs. prednisolone), immunophenotype, or white blood cell count (Table 1) . Noteworthy, age was not a criterion for risk group Of the patients with ON with available answers, four of 56 had cessation of other antileukemia drugs due to ON; in all these cases it was vincristine. Table S5 ).
Additions and modifications of ALL therapy

Patients' ON questionnaire
DISCUSSION
At 6.3%, the overall ON incidence in this study is similar to that in other studies, 8, 18 ,27,28 with female sex and older age being the most TA B L E 2 Risk factors for severe osteonecrosis and surgery This study suggests that puberty, together with differences between male and female development could play an important role in ON development. The bone is a dynamic organ and bone mass attainment during childhood and especially adolescence is essential for bone health later in life. 34 Interestingly, the median age at ALL diagnosis for males (14.9 years) and females (12.1 years) correspond with the age for peak height velocity and peak bone mass accrual. [34] [35] [36] High resolution peripheral quantitative computed tomography measurements at distal radius and tibia show increasing cortical bone mineral density (BMD) and decreasing cortical porosity during puberty in both sexes, but peri-and postpubertal males have significantly higher trabecular bone volume ratios and larger cortical crosssectional areas when compared with females. 37, 38 Already from a young age, males have larger and denser bones than females do, 37 and this may give adolescent males a bone-strength advantage that also plays a role in ON, not the least for weight-bearing joints. Several hormones, including estrogen and insulin-like growth factor, play a major role in pubertal bone mass gain 35 and likely modify the risk of ON during puberty. These aspects, including Tanner stage, need to be explored in detail in prospective studies with comprehensive data collection on skeletal and endocrine factors during puberty.
Interestingly, young children were likely to be diagnosed with ON earlier than adolescents and young adult patients were; this did not appear to be accounted for by delayed diagnosis in the latter groups.
We speculate whether the underlying mechanism, as well as the genetic risk factors important for developing ON, may differ across age groups. A previous study has explored genetic risk factors for ON in young children, 39 but it is unknown whether predisposing host genome variants differ by age group. Moreover, while the highest risk of developing ON is in the adolescent and young adult group, one-third of all patients with ON (n = 20) were younger than 10 years of age.
The median time from ALL diagnosis to ON diagnosis (Time ON ) of 1.4 years corresponds with one previous report, 9 although it was longer compared with other studies, 8, 28 potentially reflecting inclusion criteria amongst other things. Since ON may become symptomatic many years after the end of therapy, this complication should be kept in mind at follow-up visits until 5 years from ALL diagnosis, at least for older patients.
The majority of patients with severe ON still experienced symptoms at the time of the survey, and some were regularly using walking aids and medication to reduce pain, emphasizing that severe ON is a long-term complication with decreased quality of life. 40 and are used to treat primary and secondary osteoporosis in pediatric patients. 41 In addition to pain relief, the use of bisphosphonates might improve the outcome of ON, 42 but this needs to be investigated in a randomized trial.
ON is associated with use of GC. 18 However, despite alternateweek dexamethasone, which significantly reduces incidence of ON, 18 we observed a high cumulative incidence of symptomatic ON especially in adolescents and adults. The extensive use of asparaginase in the NOPHO ALL2008 protocol may influence GC pharmacokinetics [43] [44] [45] and also aggravate hyperlipidemia, 44, 46, 47 which has been proposed to be a risk factor for ON. 17, 48 Considering the high incidence of symptomatic ON, randomized interventions could be considered investigating possible steps for preventing ON by changes in both doses and timing of dexamethasone as well as asparaginase. This hypothesis is being tested in the NOPHO ALL2008 randomized trial using PEG-ASP every 2 weeks versus every 6 weeks (clinicaltrials.gov no.: NCT00819351).
This study includes patients who were all treated according to the same NOPHO ALL2008 protocol using a unique prospective standardized online toxicity registration, 22 which strengthens the study. The study included a case-control study, allowing us to investigate potential risk factors besides age and sex. The response rate for physicians' questionnaires for both patients with ON and controls was high, which reduces the risk of selection bias. For the questionnaires for patients/families, the response rate was lower but still considered acceptable as the number of patients with non-severe/severe grade ON and available questionnaires was fairly representative of the total ON cohort. The retrospective study design could introduce recall bias in the questionnaire for patients/families. Moreover, all questionnaires underwent validation to avoid misinterpretation.
In conclusion, the significant diversity in frequency and risk factors across age groups and by sex emphasizes the need for large international studies to address in depth phenotype diversity and risk factors, and ultimately develop effective interventions.
